|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.02 CAD | -1.92% |
|
-1.92% | +13.33% |
| 05-07 | ZYUS Life Sciences Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 04-23 | ZYUS Life Sciences Receives US Patent for Pain Management Drug Candidate | MT |
ZYUS Life Sciences Corporation reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was CAD 0.351 million compared to CAD 0.298 million a year ago. Net loss was CAD 42.59 million compared to CAD 24.66 million a year ago.
Basic loss per share from continuing operations was CAD 0.76. Diluted loss per share from continuing operations was CAD 0.76.
| 1st Jan change | Capi. | |
|---|---|---|
| +13.33% | 52.9M | |
| +67.53% | 63.85B | |
| -0.77% | 41.83B | |
| +45.66% | 40.65B | |
| -10.72% | 27.12B | |
| +13.30% | 26.52B | |
| -22.79% | 18.69B | |
| +4.70% | 12.73B | |
| +24.10% | 12.11B | |
| +27.41% | 12.07B |
ZYUS LIFE SCIENCES CORPORATION 
